{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:52:05Z","timestamp":1788292325069,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010441","name":"Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To explore the benefit of adaptive magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) for treatment of lung tumors in different locations with a focus on ultracentral lung tumors (ULT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients &amp;amp; Methods<\/jats:title><jats:p>A prospective cohort of 21 patients with 23 primary and secondary lung tumors was analyzed. Tumors were located peripherally (N = 10), centrally (N = 2) and ultracentrally (N = 11, planning target volume (PTV) overlap with proximal bronchi, esophagus and\/or pulmonary artery). All patients received MRgSBRT with gated dose delivery and risk-adapted fractionation. Before each fraction, the baseline plan was recalculated on the anatomy of the day (predicted plan). Plan adaptation was performed in 154\/165 fractions (93.3%). Comparison of dose characteristics between predicted and adapted plans employed descriptive statistics and Bayesian linear multilevel models. The posterior distributions resulting from the Bayesian models are presented by the mean together with the corresponding 95% compatibility interval (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Plan adaptation decreased the proportion of fractions with violated planning objectives from 94% (predicted plans) to 17% (adapted plans). In most cases, inadequate PTV coverage was remedied (predicted: 86%, adapted: 13%), corresponding to a moderate increase of PTV coverage (mean +6.3%, 95% CI: [5.3\u20137.4%]) and biologically effective PTV doses (BED<jats:sub>10<\/jats:sub>) (BED<jats:sub>min<\/jats:sub>: +9.0 Gy [6.7\u201311.3 Gy], BED<jats:sub>mean<\/jats:sub>: +1.4 Gy [0.8\u20132.1 Gy]). This benefit was smaller in larger tumors (\u22120.1%\/10 cm\u00b3 PTV [\u22120.2 to \u22120.02%\/10 cm\u00b3 PTV]) and ULT (\u22122.0% [\u22123.1 to \u22120.9%]). Occurrence of exceeded maximum doses inside the PTV (predicted: 21%, adapted: 4%) and violations of OAR constraints (predicted: 12%, adapted: 1%, OR: 0.14 [0.04\u20130.44]) was effectively reduced. OAR constraint violations almost exclusively occurred if the PTV had touched the corresponding OAR in the baseline plan (18\/19, 95%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adaptive MRgSBRT is highly recommendable for ablative treatment of lung tumors whose PTV initially contacts a sensitive OAR, such as ULT. Here, plan adaptation protects the OAR while maintaining best-possible PTV coverage.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.757031","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T07:19:18Z","timestamp":1641885558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations"],"prefix":"10.3389","volume":"11","author":[{"given":"Sebastian","family":"Regnery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Buchele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Eichkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ristau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Rippke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-Term Follow-Up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT","volume":"20","author":"Horner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.108","article-title":"Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases From Renal Cell Carcinoma-a Multicenter Analysis of the German Working Group \"Stereotactic Radiotherapy\"","volume":"9","author":"Hoerner-Rieber","year":"2017","journal-title":"J Thorac Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.01.010","article-title":"Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Improving Overall Survival and Identifying Subgroups at High Risk of Local Failure","volume":"145","author":"Pasalic","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","article-title":"Definition of Stereotactic Body Radiotherapy: Principles and Practice for the Treatment of Stage I non-Small Cell Lung Cancer","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahlenther und Onkologie Organ der Dtsch Rontgengesellschaft"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.01.032","article-title":"Benefit of Respiration-Gated Stereotactic Radiotherapy for Stage I Lung Cancer: An Analysis of 4DCT Datasets","volume":"62","author":"Underberg","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.radonc.2019.10.013","article-title":"Stereotactic MR-Guided Adaptive Radiation Therapy for Peripheral Lung Tumors","volume":"144","author":"Finazzi","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","article-title":"Dose-Response Relationship for Image-Guided Stereotactic Body Radiotherapy of Pulmonary Tumors: Relevance of 4D Dose Calculation","volume":"74","author":"Guckenberger","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318260e00d","article-title":"A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non-Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy","volume":"7","author":"Grills","year":"2012","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00215","article-title":"Parenchymal and Functional Lung Changes After Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences From a Single Institution","volume":"7","author":"H\u00f6rner-Rieber","year":"2017","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70168-3","article-title":"Stereotactic Ablative Radiotherapy Versus Lobectomy for Operable Stage I Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ctro.2019.04.007","article-title":"Technical Design and Concept of a 0.35 T MR-Linac","volume":"18","author":"Kl\u00fcter","year":"2019","journal-title":"Clin Trans Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.08.003","article-title":"MRI-Linear Accelerator Radiotherapy Systems","volume":"30","author":"Liney","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13014-019-1314-0","article-title":"Comparison of Treatment Plans Between IMRT With MR-Linac and VMAT for Lung SABR","volume":"14","author":"Park","year":"2019","journal-title":"Radiat Oncol (Lond Engl)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.03.035","article-title":"Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors","volume":"104","author":"Finazzi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial","volume":"4","author":"Henke","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.11.009","article-title":"Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis","volume":"101","author":"van Herk","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.07.5937","article-title":"Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal Complications After Stereotactic Body Radiation Therapy for Central Lung Tumors Abutting the Proximal Bronchial Tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients With \"Ultracentral\" Non-Small Cell Lung Cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1552375","article-title":"Is Stereotactic Body Radiotherapy for Ultra-Central Lung Tumor a Feasible Option","volume":"95","author":"Rim","year":"2019","journal-title":"A Syst Rev Meta-Anal Int J Radiat Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial-A Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.02.025","article-title":"Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors","volume":"107","author":"Finazzi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01578-z","article-title":"First Prospective Clinical Evaluation of Feasibility and Patient Acceptance of Magnetic Resonance-Guided Radiotherapy in Germany","volume":"196","author":"Kl\u00fcter","year":"2020","journal-title":"Strahlenther und Onkologie Organ der Dtsch Rontgengesellschaft"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and Robust Online Adaptive Planning in Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Pancreatic Cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2020.12.005","article-title":"A Practical Implementation of Risk Management for the Clinical Introduction of Online Adaptive Magnetic Resonance-Guided Radiotherapy","volume":"17","author":"Kl\u00fcter","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"Brms: An R Package for Bayesian Multilevel Models Using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J\u00a0Stat Software"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2423","DOI":"10.7759\/cureus.2423","article-title":"Feasibility of Adaptive MR-Guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors","volume":"10","author":"Padgett","year":"2018","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.03.005","article-title":"Correlating Dose Variables With Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments","volume":"107","author":"Klement","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s0167-8140(87)80151-2","article-title":"The Dose-Rate Effect in Human Tumour Cells","volume":"9","author":"Steel","year":"1987","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(03)00499-1","article-title":"Impact of Prolonged Fraction Delivery Times on Tumor Control: A Note of Caution for Intensity-Modulated Radiation Therapy (IMRT)","volume":"57","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.03.014","article-title":"Dose-Rate Effects in External Beam Radiotherapy Redux","volume":"95","author":"Ling","year":"2010","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa093","article-title":"Stereotactic Body Radiotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer: Does Beam-on Time Matter","volume":"50","author":"Hurmuz","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.01.004","article-title":"Loss of Biological Effect in Prolonged Fraction Delivery","volume":"59","author":"Fowler","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phro.2020.05.002","article-title":"Delivery of Magnetic Resonance-Guided Single-Fraction Stereotactic Lung Radiotherapy","volume":"14","author":"Finazzi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.04.046","article-title":"Serial Megavoltage CT Imaging During External Beam Radiotherapy for Non-Small-Cell Lung Cancer: Observations on Tumor Regression During Treatment","volume":"63","author":"Kupelian","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.11.003","article-title":"Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-Optimized Fractionation Scheme","volume":"22","author":"Regnery","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T07:19:22Z","timestamp":1641885562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":40,"alternative-id":["10.3389\/fonc.2021.757031"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.757031","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"757031"}}